簡體|繁體
Introduction

Essex Bio-Technology Limited (“EssexBio Group” and the “Company”) was incorporated in the Cayman Islands on 31st July, 2000 and has been listed on the Stock Exchange of Hong Kong since 27th June, 2001.
 

Essex specializes in biopharmaceutical drug development based on recombinant DNA technology. It is principally engaged in the manufacture and sale of biopharmaceutical products for the treatment and healing of surface wounds and eye wounds. The Group also engaged in the research and development of bFGF products for new indications, as well as other ophthalmic pharmaceutical projects.
 

A series of genetically engineered bio-pharmaceutical drugs have been successfully developed and three of them were classified as State-level Category I new drugs. The main brands of the Company's products are Beifuji, Beifushu and Beifuxin.

 

网上购买彩票 腾讯彩分分稳赚方案 买彩票把所有钱输光了 重庆时时开奖历史查询 追牧文化靠什么赚钱 股票涨跌指标 蚂蚁威客怎么赚钱 捕鱼合集水果拉霸攻略 pk10最牛稳赚模式4码 全天重庆时时计划手机软件 天津时时官方投注 血拼斗地主支持三人癞子比赛玩法 六肖中特最准一肖 彩金捕鱼掉落红包 11选5顺口溜 网络捕鱼游戏赌钱 红树林时时彩平台